Log in
NASDAQ:HZNP

Horizon Therapeutics Public Stock Forecast, Price & News

$71.72
+0.50 (+0.70 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$71.40
Now: $71.72
$73.86
50-Day Range
$68.52
MA: $73.90
$80.92
52-Week Range
$23.81
Now: $71.72
$86.67
Volume3.01 million shs
Average Volume2.30 million shs
Market Capitalization$15.83 billion
P/E Ratio19.60
Dividend YieldN/A
Beta1.32
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Horizon Therapeutics Public logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 4.4 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.36 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:HZNP
CUSIP44047T10
Phone011-353-1772-2100
Employees1,200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.30 billion
Cash Flow$3.61 per share
Book Value$17.20 per share

Profitability

Net Income$573.02 million

Miscellaneous

Market Cap$15.83 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$71.72
+0.50 (+0.70 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Horizon Therapeutics Public (NASDAQ:HZNP) Frequently Asked Questions

How has Horizon Therapeutics Public's stock price been impacted by COVID-19 (Coronavirus)?

Horizon Therapeutics Public's stock was trading at $30.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HZNP stock has increased by 135.1% and is now trading at $71.72.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Horizon Therapeutics Public?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Horizon Therapeutics Public
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Horizon Therapeutics Public?

Wall Street analysts have given Horizon Therapeutics Public a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Horizon Therapeutics Public wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Horizon Therapeutics Public's next earnings date?

Horizon Therapeutics Public is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Horizon Therapeutics Public
.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) released its quarterly earnings results on Saturday, November, 7th. The biopharmaceutical company reported $1.74 earnings per share for the quarter, beating analysts' consensus estimates of $0.97 by $0.77. The biopharmaceutical company earned $636.40 million during the quarter, compared to analyst estimates of $531.11 million. Horizon Therapeutics Public had a return on equity of 25.66% and a net margin of 43.55%. Horizon Therapeutics Public's revenue for the quarter was up 89.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.64 EPS.
View Horizon Therapeutics Public's earnings history
.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public issued an update on its FY 2020 Pre-Market earnings guidance on Monday, November, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.12-2.14 billion, compared to the consensus revenue estimate of $1.95 billion.

What price target have analysts set for HZNP?

11 equities research analysts have issued 12 month price targets for Horizon Therapeutics Public's shares. Their forecasts range from $35.00 to $112.00. On average, they anticipate Horizon Therapeutics Public's share price to reach $81.17 in the next twelve months. This suggests a possible upside of 13.2% from the stock's current price.
View analysts' price targets for Horizon Therapeutics Public
.

Are investors shorting Horizon Therapeutics Public?

Horizon Therapeutics Public saw a increase in short interest in November. As of November 15th, there was short interest totaling 6,300,000 shares, an increase of 22.8% from the October 31st total of 5,130,000 shares. Based on an average trading volume of 2,190,000 shares, the days-to-cover ratio is presently 2.9 days.
View Horizon Therapeutics Public's Short Interest
.

Who are some of Horizon Therapeutics Public's key competitors?

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

Who are Horizon Therapeutics Public's key executives?

Horizon Therapeutics Public's management team includes the following people:
  • Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 53, Pay $4.73M)
  • Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 55, Pay $1.67M)
  • Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 66, Pay $1.46M)
  • Mr. Vikram Karnani, Exec. VP & Pres of International (Age 45, Pay $1.34M)
  • Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 55)
  • Dr. Karin Rosen M.D., Ph.D., Exec. VP of R&D and Chief Scientific Officer
  • Ms. Tina E. Ventura, Sr. VP of Investor Relations
  • Mr. Brian K. Beeler, Exec. VP & Gen. Counsel (Age 47)
  • Mr. Timothy Ayers, Chief Compliance Officer & VP
  • Mr. Geoffrey M. Curtis, Exec. VP of Corp. Affairs & Chief Communications Officer (Age 45)

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.23%), William Blair Investment Management LLC (2.65%), Allianz Asset Management GmbH (1.67%), Nuveen Asset Management LLC (1.47%), State Street Corp (1.13%) and Standard Life Aberdeen plc (0.99%). Company insiders that own Horizon Therapeutics Public stock include Barry Moze, Brian K Beeler, Daniel A Camardo, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani.
View institutional ownership trends for Horizon Therapeutics Public
.

Which institutional investors are selling Horizon Therapeutics Public stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Samlyn Capital LLC, Charles Schwab Investment Management Inc., AQR Capital Management LLC, Jennison Associates LLC, Scout Investments Inc., Polar Capital LLP, and Emerald Advisers LLC. Company insiders that have sold Horizon Therapeutics Public company stock in the last year include Barry Moze, Brian K Beeler, Daniel A Camardo, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, and Vikram Karnani.
View insider buying and selling activity for Horizon Therapeutics Public
.

Which institutional investors are buying Horizon Therapeutics Public stock?

HZNP stock was purchased by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Nuveen Asset Management LLC, Morgan Stanley, Point72 Asset Management L.P., Wells Fargo & Company MN, Smith Asset Management Group LP, ExodusPoint Capital Management LP, and Bain Capital Public Equity Management II LLC.
View insider buying and selling activity for Horizon Therapeutics Public
.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $71.72.

How big of a company is Horizon Therapeutics Public?

Horizon Therapeutics Public has a market capitalization of $15.83 billion and generates $1.30 billion in revenue each year. The biopharmaceutical company earns $573.02 million in net income (profit) each year or $1.94 on an earnings per share basis. Horizon Therapeutics Public employs 1,200 workers across the globe.

What is Horizon Therapeutics Public's official website?

The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.